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Synthesis of benzonaphthofuroquinones and
benzoylnaphthindolizinediones by reactions of
flavonoids with dichlone under basylous,
oxygenous and aqueous conditions: their cytotoxic
and apoptotic activities†
Peng Luo,ac Wanxing Wei,a Saqlain Haider,b Shabana I. Khan,b Mei Wang,b
Weigao Pan *ac and Amar G. Chittiboyina*b
Using flavonoids and dichlone as substrates, benzonaphthofuroquinones (1, 2, 3, 5, 6, novel; 4 new) and
benzoylnaphthindolizinediones (7, 8, known; 9, new) were synthesized through common base-catalyzed
method and a new method of combining base-catalyzed with O2/H2O exposing. The possible reaction
mechanisms may involve the process like isomerization, hydration, oxidation, decomposition and
intermolecular condensation. Benzonaphthofuroquinones (2, 3, 4, 5) were found to exhibit potent
cytotoxicity against carcinoma cell lines and low toxicity to normal cell lines. The compounds 4 and 5
not only expressed a significant late-stage-apoptosis against human leukemia and melanoma, but also
promoted the cleavage of caspase-3 and PARP in human leukemia, which suggested that the late-stage-
apoptosis and caspase-3 pathway may be responsible for the cytotoxicities of these
benzonaphthofuroquinones. The replacement of the furan ring with pyrrole system in
benzoylnaphthindolizinediones (7, 8, 9) resulted in the loss of anticancer activity.
1. Introduction
Quinones, an important class of compounds, are found in many
biochemical systems. Anticancer drugs like daunorubicin and
mitomycin C are known to contain the quinone scaffold in their
structures. Their cytotoxic activity is attributed to different
mechanisms including redox cycling, intercalation of DNA
strands, free radical generation and alkylation via quinone
methide formation.1,2
Dunnione analogs, members of naphthoquinones family,
were found to exhibit potent cytotoxicity against breast and
pancreatic cancer cell lines (Scheme 1, A1–A3).3 Presence of
a phenolic hydroxy group at C-5 position in 2,3-dihydro-5-
hydroxy-2-(prop-1-en-2-yl)naphtho[2,3-b]furan-4,9-dione
(Scheme 1, A4) results in an increase in the antiproliferative
effects.1 a-Dunnione (CS-3, Scheme 1, A3) inhibited the respi-
ration of the tumor cells by interfering with the electron
transport at some point between NADH and ubiquinone which
mechanism give poor selectivity for cytotoxicities between
carcinoma and normal cells, and its furan ring attached to the
naphthoquinone scaffold along with the lipophilic character of
the alkyl substituents is a key feature required for the
enhancement of anticancer activity.4 While, dinaphtho[1,2-
b:20,30-d]furan-7,12-dione derivatives (Scheme 1, A5), with
additional naphtha-moiety on a-dunnione, had anticancer
mechanisms of topoisomerase-I mediated DNA cleavage,
epidermal and vascular endothelial growth factor receptors
inhibitory actions, which mechanisms owned high selectivity
for cytotoxicities.5
So modifying dunniones with aromatic ring-group may be
a good way to achieve anticancer mechanisms correlated with
cancer-related-biomacromolecules, which may result in high
selectivity for cytotoxicity. Flavonoids were potential phenol
source for modifying uses, in which the two phenol moieties
and a variable central-three-carbons-chain may provide various
substituent groups. Meanwhile, constructing other phenol-
modied a-dunnione-like derivatives (such as using pyrrol
system instead of furan system) may be useful to investigate the
changes of cytotoxicities or anticancer mechanisms.
In reported methods, benzo- or naphthanaphthofur-
oquinones (a-dunniones analogs) was synthesized mainly
through base-catalyzed condensation reaction. Condensation of
dichlone with methyl 1,4-dihydroxy-2-naphthoate or 2-acetyl-
1,4-dihydronaphthalene with presence of K2CO3 under reux
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in pyridine at 90 C resulted in dinaphtho[1,2-b:20,30-d]furan-
7,12-dione (Scheme 2, B1)6 or 6-acetyl-5-hydroxydinaphtho[2,3-
b:20,10-d]furan-7,12-dione (Scheme 2, B2),7 respectively. [1,3]
Dioxolo[4,5-f]naphtho[2,3-b]benzofuran-6,11-dione (Scheme 2,
B3) or 1,3-dihydroxybenzo[b]naphtho[2,3-d]furan-6,11-dione
(Scheme 2, B4) was synthesized from the reaction of dichlone
with sesamol (or phloroglucinol) in presence of KOH under
reux in pyridine at 90 C (or 30 C).8
Intermolecular C–C-bond formation and intermolecular O-
alkylation were the two condensation processes for the
synthesis of naphthofuroquinones scaffold. Other methods of
preparation included light irradiation and oxidation were re-
ported. 2-Hydroxynaphtho-1,4-dione was converted to negative
ion by pyrex-ltered light, and reacted with 2-naphthol exciplex
to produce a C–C bond rstly, and then to form a C–O bond by
dehydration.9 Quinone-arenols were prepared from hydroqui-
none monomethylethers by oxidants to form C–C bond in the
rst step, and by oxidative cyclization of quinone-arenols to give
C–O bond in the second step to produce
dibenzofuranquinones.10
In reported methods, benzoylnaphthindolizinediones (a-
dunnione-like compounds) were synthesized by potassium
carbonate-catalyzed one-pot tandem reactions of the N-ylides
with 2,3-dichloro-1,4-naphthoquinone (Scheme 3, (1)),11 or by
copper(II)-catalyzed three-component reactions of 2-bromoace-
tophenone, 1,4-naphthoquinone, and pyridine via sp2-C–H
difunctionalization of naphthoquinone followed by intra-
molecular cyclization and oxidative aromatization (Scheme 3,
(2)),12 or by iodine oxidation of 2-alkyl-1,4-naphthoquinones in
the presence of substituted pyridines (Scheme 3, (3)).13
In our initial plan, in order to get naphthanaphthofur-
oquinones, dihydroavone and chalcone were respectively used
to react with dichlone in pyridine under anoxic and anhydrous
conditions, however, no targeted products were obtained.
Unintentionally, the anoxic and anhydrous conditions being
removed and reaction system being exposed to the moist air,
unexpected benzoylnaphthindolizinediones were found. So this
O2/H2O exposing combining with base-catalyzed method were
developed.
With regard to recent works about the utilization of water to
promote reaction, ecofriendly and efficient synthesis of sulfo-
nylated N-heteroaromatics14 and 2-sulfonyl quinolines/pyri-
dines15 were conducted in water, and in the iodine-catalyzed
odorless synthesis of S-thiocarbamates, water played a dual
role, viz. co-solvent and H/O source.16
Scheme 1 The reported dunnione analogs with cytotoxicity.
Scheme 2 The reported synthetic methods for benzo- or naphthanaphthofuroquinones.


































































































2. Results and discussion
2.1 Chemistry
2.1.1 Structure elucidation and characterization. Ten

















Structures of 1–10 were elucidated and characterized by
NMR (1H, 13C, DEPT, 1H–1H COSY, HSQC, HMBC), MS (ESI-MS,
APCI-MS and HR ESI-MS) and IR spectra (see the ESI† le).
In NMR spectra of 1, total of seven aromatic methines
signals were observed. As concerns resonances changes occur-
ring on the B-ring of avonoid moiety, one methane signal at
dH/dC 7.36(s)/118.6 (position 15) was remained while the other
one disappeared, which suggested that intermolecular C–C
condensation reaction occurred in position 11. Furthermore,
a new aromatic oxygenated carbon signal at dC 154.1 (C-2) was
found, so an additional C–O covalent bond was formed, which
contributed to produce the furan ring (Scheme 4). As compared
with H-15/C-15 resonances of 1 at dH-15/dC-15 7.36/118.6, the
corresponding resonances of 2 moved to up-eld shi at dH-15/
dC-15 7.29/113.3, and as to 3, dH-15 move to down-eld shi at
7.56 while dC-15 almost unchanged at 117.8, which meaned that
the second dichlone moiety, through intermolecular O-alkyl-
ation condensation, was located at 14-O (ortho effect) in 2, and
at 13-O in 3 (Scheme 4).
In case of 5, eight aromatic methines signals were found. As
for resonances changes occurring on the B-ring of avonoid
moiety, two methine-protons signals at dH 7.22–7.24 (1H, d, J ¼
8.3 Hz)] and dH 7.61–7.63 (1H, d, J ¼ 8.3 Hz) with their coupling
in 1H–1H COSY were observed while the third one vanished,
which meant that C–C condensation reaction occurred in
position 11 (Scheme 4). Furthermore, a new aromatic oxygen-
ated carbon signal at dC 154.7 (C-2) was found, so an additional
C–O covalent bond was formed to produce the furan ring
(Scheme 4). 6 manifested obvious proton/carbon resonances
changes on the B-ring comparing to those of 5, so the second
naphthoquinone moiety was located at 13-O (Scheme 4). 4 was
produced from 5 (Scheme 4), so the hydroxyl group was located
at position 13, which had been conrmed by its NMR data and
single crystal structure in our previous work.17
7 had been conrmed by its NMR data and single crystal
structure in our previous work.18
By the coupling relationships in 1H–1H COSY of 8, proton
signals of dH 7.91–7.93 (2H, d, J ¼ 7.5 Hz), 7.46–7.49 (2H, t, J ¼
7.5 Hz), 7.60–7.63 (1H, t, J ¼ 7.5 Hz) were assigned to a ve-
consecutive-methines-chain of phenyl group. Considering the
facts that the HR ESI-MS spectra gave a molecular formula of
C23H13NO3 and pyridine was used as solvent in the reaction,
proton signals of dH 9.83–9.85 (1H, d, J¼ 7.0 Hz), 7.21–7.24 (1H,
t, J ¼ 7.3 Hz), 7.41–7.44 (1H, m), 7.97–7.99 (1H, d, J ¼ 9.0 Hz)
were assigned to a four-consecutive-methines-chain of pyridine
moiety by the 1H–1H COSY coupling relationships, whichmeant
that pyridine was involved in the intermolecular condensation
reaction (Scheme 5).
Instead of ve consecutive coupling protons in 8, four
protons with coupling relationships between signals of dH 6.80–
6.82 (2H, d, J ¼ 8.5 Hz) and those of dH 7.73–7.77 (2H, m) were
Scheme 3 The reported synthetic methods for benzoylnaphthindolizinediones.


































































































observed in 9. Furthermore, one more aromatic oxygenated
carbon at dC 162.8 was found in 9 than in 8 (Scheme 5).
2.1.2 Synthesis and discussion for reaction mechanisms.
The preparations of 1, 2, 3, 5, 6 were conducted by common
methods6,7 using avonols (myricetin or quercetin) as
substrates under pyridine-catalyzed conditions (Scheme 4).
Besides mono condensation products (1, 5), additional dichlone
molecule was introduced to form bis-naphthoquinones
compounds (2, 3, 6) merely by intermolecular C–O condensa-
tion (Scheme 4).
The structure of 4 was conrmed by both single crystal X-ray
diffraction and NMR-spectrum in our previous work.17 In the
condensation reaction of quercetin with dichlone under basy-
lous, anoxic and anhydrous conditions, 4 was not found, while
providing additional condition of O2/H2O exposing, 4 was ob-
tained (Scheme 4). It may indicate that C-ring of avonol moiety
in 5 was cleaved by hydration, and then a “2,3-dioxo-3-(2,4,6-
trihydroxyphenyl)propanal” group was eliminated to give
a benzonaphthofuroquinone core (4, Scheme 4). However, this
“2,3-dioxo-3-propanal” elimination mechanism was not found
in the literature, so further work should be done to conrm it.
In Scheme 5, occurrence of side product (10) provided
evidence for the existence of intermediate of dichlone reacted
with pyridine, and the structure of 10 and its synthetic method
(under similar conditions and using the same substrates) were
reported by Andreas Schmidt et al.19 Dihydroavone (nar-
ingenin) isomerized into trans-chalcone. Acetophenone blocks,
which were generated from trans-chalcone via retro-aldol
decomposition aer hydration and isomerization, reacted
with above intermediate to build a benzoylnaph-
thindolizinedione skeleton (7, 8, 9, Scheme 5). The fact that 7
and 8 were derived from the different part of chalcone provided
evidence for the isomerization reaction of chalcone hydrate.
Two phases of the hydration and dealdolization reactions of
chalcone (1,3-diphenyl-2-propen-1-one) and their reaction rate
constants were reported by J. Peter Guthrie et al. Hydration of
chalcone was catalyzed by aqueous sodium hydroxide to give the
hydrate (1,3-diphenyl-3-hydroxy-1-propanone) rstly, and then
retro-aldol reaction of this hydrate was also catalyzed by aqueous
sodium hydroxide to produce benzaldehyde and acetophenone.20
2.2 Biology
2.2.1 Cytotoxicity. Some of the benzonaphthofuroquinones
(1, 2, 3, 4, 5) exhibited anticancer effects, while the benzoyl-
naphthindolizinediones (7, 8, 9) showed no activities (Table 1).
The formed furan-ring in benzonaphthofuroquinones being
replaced by pyrrol-ring in benzoylnaphthindolizinediones
resulted in the loss of anticancer activity (Table 1).
Doxorubicin manifested strong cytotoxicities against both
carcinoma and normal cell lines, while 1, 2, 3, 4, 5 possessed
good anticancer activities and low toxicity to normal cells. 3
owed high antagonistic effect against almost all test solid
carcinoma cell lines, while 2, 5 just showed good inhibition
against SK-MEL (solid carcinoma), and 4, 5 had good inhibition
Scheme 4 Synthesis of benzonaphthofuroquinones and the possible reaction mechanism of 4. Reagents and conditions: (1) pyridine, 85 C,
24 h; (2) pyridine, moist air (O2/H2O) injection, 85 C, 24 h.


































































































against HL-60 (non-solid carcinoma) (Table 1). The potent
cytotoxic derivatives (2, 3, 4, 5) were selected for further
apoptotic test and western blotting analysis.
2.2.2 Apoptosis. In the case of apoptosis against human
leukemia (Fig. S1,† see the ESI†), 2 (20 mM) showed no apoptotic
activity; and 3 (20 mM) manifested some slight late-stage-
apoptosis (Q2, Annexin V+/7-AAD+) and early-stage-apoptosis
(Q3, Annexin V+/7-AAD); while 4, 5 signicantly induced
Annexin V-positive apoptosis (with apoptotic proportions of
53.7% and 27.9%, respectively) at low concentration (5 mM), and
the apoptotic proportions mainly distributed in the upper right
quadrant (Annexin V+/7-AAD+, late-apoptotic-stage) with
proportions of 36.8% and 20.1%, respectively.
With regard to apoptosis against melanoma (Fig. S2,† see the
ESI†), 2 (30 mM) and 3 (30 mM) had no apoptotic activities; while
4 (30 mM) and 5 (30 mM) induced obvious Annexin V-positive
apoptosis (45.8% and 17.0%, respectively), in which, the
major apoptotic proportions (41.7% and 15.1%, respectively)
Scheme 5 Synthesis of benzoylnaphthindolizinediones and the possible reaction mechanisms. Reagents and conditions: pyridine, moist air (O2/
H2O) injection, 85 C, 24 h.
Table 1 Cytotoxicities against carcinoma and normal cell lines
Treatments
Cancer cell linesc (IC50, mM)
Non-cancer cell linesd
(IC50, mM)
SK-MEL KB BT-549 SK-OV-3 HL-60 LLC-PK1 Vero
1 14.83 29.66 23.31 NAa NAa NCa NCa
2 3.88 10.87 10.87 27.95 18.17 24.84 38.82
3 2.02 5.90 3.57 6.21 17.32 27.95 15.53
4 12.88 37.88 37.88 22.73 2.57 18.18 15.91
5 5.26 10.96 28.51 21.93 4.29 21.93 NCa
6 39.8 NAa NAa NAa NAa 39.8 NCa
7 NAa NAa NAa NAa NAa NCa NCa
8 NAa NAa NAa NAa NAa NCa NCa
9 NAa NAa NAa NAa NAa NCa NCa
Doxorubicin 1.29 0.92 1.84 4.05 —b 0.92 9.21
Cisplatin —b —b —b —b 1.46 —b —b
a NA or NC mean not active up to 40 mM. b Not tested. c SK-MEL: malignant melanoma, KB: oral epidermal carcinoma, BT-549: ductal breast
carcinoma, SK-OV-3: ovary carcinoma, HL-60: human leukemia. d LLC-PK1: kidney epithelial, VERO: African green monkey kidney broblast.


































































































were observed in the upper right quadrant (Annexin V+/7-AAD+,
late-apoptotic-stage).
2.2.3 Western blotting analysis. As to HL-60 (Fig. S3-A,† see
the ESI†), 3 (20 mM), 4 (3 mM) and 5 (5 mM) signicantly induced
the cleavage of caspase-3 and PARP, while 2 (20 mM) induced
obvious PARP-cleavage and slight caspase-3 cleavage, which
suggested that 4 and 5 own relatively higher signicant
apoptosis inducing effect. With regard to melanoma (Fig. S3-B,†
see the ESI†), 4, 5manifested slight apoptosis inducing effect at
concentration of 30 mM.
3. Experimental
3.1 General information and characterization data
Flash column chromatographic separations were accomplished
on Biotage Isolera Four system (Biotage, Uppsala, Sweden).
NMR was recorded on DRX-400 and DRX-500 NMR spectrome-
ters (Bruker, Rheinstetten, Germany). ESI-, APCI- and HR ESI-
MS were recorded on Agilent 1290 LC-MS or Agilent G6530
TOF MS spectrometer (Agilent Technologies Inc., California,
USA). Western blot results were visualized on Mini-HD9-Auto
Biomolecular imager (Leader Oriental Technology. LTD, Bei-
jing, China). Dichlone and avonoids were purchased from
Fisher Scientic (Fair Lawn, NJ, USA) and Ark Pharm, Inc.
(Arlington Heights, IL, USA). Cell lines were gotten from the
American Type Culture Collection (Manassas, VA). Caspase-3
(3G2) mouse mAb, caspase-3 antibody, cleaved caspase-3
(Asp175) (5A1E) rabbit mAb, PARP (46D11) rabbit mAb and
horseradish peroxidase (HRP) were purchased from Cell
Signaling Technology, Inc (Danvers, MA, USA).
3.1.1 Characterization data. 1: orange powder; 315 mg,
yield 45% (nal product/myricetin  100%); dp (decomposition
point) 385 C. ESI-MS: 473.0 [M + H]+, 471.0 [MH]; ACPI-MS:
473.0 [M + H]+, 471.0 [M  H]. HRESI-MS found [M  H]
471.0353; C25H11O10 [M  H] requires 471.0352. IR
(solid, cm1): 3548, 3318, 3058, 1720, 1707, 1655, 1595, 1508,
1459, 1366, 1310, 1164, 1074, 1063, 1049, 983, 964, 793, 711,
672. 1H NMR (400 MHz, DMSO-d6) d: 8.13 (1H, m, H-9), 7.90–
7.91 (1H, m, H-6), 7.84–7.86 (2H, m, H-7, 8), 7.36 (1H, s, H-15),
6.29 (1H, s, H-22), 6.24 (1H, s, H-24). 13C NMR and DEPT (101
MHz, DMSO-d6) d: 180.2 (C-4), 177.0 (C-19), 175.0 (C-1), 164.3 (C-
23), 161.5 (C-21), 157.3 (C-25), 154.1 (C-2), 148.8 (C-14), 147.0 (C-
17), 146.8 (C-12), 136.9 (C-18), 134.8 (C-7), 134.4 (C-8), 133.6 (C-
10), 133.2 (C-13), 132.1 (C-5), 127.0 (C-6), 126.4 (C-9), 125.1 (C-3),
118.6 (C-15), 116.4 (C-16), 115.1 (C-11), 104.4 (C-20), 98.6 (C-22),
93.9 (C-24). 1H was assigned to 13C by HSQC correlations. In the
1H–1H COSY spectrum, the couplings of H-6 with H-7, H-7 with
H-8, H-8 with H-9 were determined. In the HMBC spectrum, the
correlations of H-6 with C-10; H-7 with C-9; H-8 with C-6; H-9
with C-1; H-15 with C-11, 13, 14; H-22 with C-20; H-24 with C-
20, 23, 25 were observed.
2: red powder; 126 mg, yield 18% (nal product/myricetin 
100%); mp 319–320 C. ESI-MS: 659.0 [M + CH3OH–H2O + H]
+,
657.0 [M + CH3OH–H2O–H]
; ACPI-MS: 659.0 [M + CH3OH–H2O
+ H]+, 657.0 [M + CH3OH–H2O–H]
. HRESI-MS found [M  H]+
643.0463; C35H16O13 [M  H]+ requires 643.0518. IR
(solid, cm1): 3530, 3078, 1671, 1655, 1627, 1606, 1588, 1498,
1383, 1363, 1322, 1286, 1246, 1186, 1161, 1112, 1051, 975, 897,
841, 794, 711, 655. 1H NMR (400 MHz, DMSO-d6) d: 8.10–
8.12(1H, m, H-9), 7.99–8.01 (2H, m, H-31, 34), 7.94–7.96 (2H, m,
H-32, 33), 7.92–7.94 (1H, m, H-6), 7.84–7.86 (2H, m, H-7, 8), 7.29
(1H, s, H-15), 6.40 (1H, s, H-24), 6.20 (1H, s, H-22). 13C NMR and
DEPT (101 MHz, DMSO-d6) d: 182.3 (C-4), 177.4 (C-29), 176.9 (C-
19), 176.6 (C-26), 174.9 (C-1), 165.0 (C-23), 162.0 (C-21), 160.1 (C-
27), 156.9 (C-25), 153.5 (C-14), 148.3 (C-17), 140.6 (C-2), 140.2 (C-
12), 139.5 (C-28), 138.5 (C-18), 134.9 (C-7, 32, 33), 134.7 (C-8),
132.7 (C-10), 132.2 (C-13), 131.1 (C-5), 130.6 (C-16), 130.2 (C-
35), 130.0 (C-30), 127.0 (C-3), 126.9 (C-31), 126.5 (C-9), 126.3
(C-34), 126.2 (C-6), 113.3 (C-15), 110.7 (C-11), 105.1 (C-20), 99.5
(C-22), 94.4 (C-24). 1H was assigned to 13C by HSQC correlations.
In the 1H–1H COSY spectrum, the couplings of H-6 with H-7, H-
7 with H-8, H-8 with H-9, H-31 with H-32, H-32 with H-33, H-33
with H-34 were determined. In the HMBC spectrum, the
correlations of H-6 with C-7, 8; H-9 with C-7, 8; H-15 with C-11,
13, 14, 17; H-22 with C-20, 24; H-31 with C-33; H-34 with C-32
were observed.
3: black powder; 112 mg, yield 16% (nal product/myricetin
 100%); mp 425–426 C. ESI-MS: 659.0 [M + CH3OH–H2O +
H]+, 656.8 [M + CH3OH–H2O–H]
; ACPI-MS: 657.0 [M + CH3OH–
H2O–H]
. HRESI-MS found [M  H]+ 643.0463; C35H16O13 [M 
H]+ requires 643.0518. IR (solid, cm1): 3647, 3317, 3071, 1673,
1645, 1630, 1603, 1591, 1571, 1508, 1474, 1434, 1369, 1320,
1277, 1246, 1226, 1211, 1178, 1156, 1104, 1060, 1010, 974, 948,
916, 900, 887, 833, 789, 750, 710, 695. 1H NMR (400 MHz,
DMSO-d6) d: 8.09–8.11 (1H, m, H-9), 8.04–8.05 (1H, m, H-34),
7.99–8.01 (1H, m, H-31), 7.89–7.90 (1H, m, H-6), 7.87–7.88
(2H, m, H-32, 33), 7.82–7.86 (2H, m, H-7, 8), 7.56 (1H, s, H-15),
6.22 (2H, s, H-22, 24). 13C NMR and DEPT (101 MHz, DMSO-d6)
d: 179.4 (C-4), 177.0 (C-29), 177.0 (C-19), 176.8 (C-26), 174.9 (C-
1), 164.5 (C-23), 161.5 (C-21), 157.3 (C-25), 156.2 (C-27), 146.2
(C-17), 143.3 (C-2), 140.6 (C-14), 139.6 (C-28), 138.9 (C-12), 137.7
(C-18), 135.1–135.2 (C-7, 32, 33), 134.6 (C-8), 133.5 (C-10), 131.8
(C-5), 130.0 (C-35), 129.9 (C-30), 128.5 (C-13), 127.2 (C-6), 126.6
(C-9), 126.4 (C-31, 34), 124.0 (C-3), 123.0 (C-16), 121.1 (C-11),
117.8 (C-15), 104.6 (C-20), 98.8 (C-22), 94.0 (C-24). 1H was
assigned to 13C by HSQC correlations. In the 1H–1H COSY
spectrum, the couplings of H-6 with H-7, H-7 with H-8, H-8 with
H-9, H-31 with H-32, H-32 with H-33, H-33 with H-34 were
determined. In the HMBC spectrum, the correlations of H-6
with C-5; H-7 with C-9; H-8 with C-10; H-9 with C-7; H-15 with
C-11, 13, 14, 17; H-22 with C-20, 21, 23, 24; H-24 with C-20, 22,
23, 25; H-31 with C-33; H-32 with C-33, 34; H-33 with C-31, 32; H-
34 with C-32 were observed.
4: red columnar crystals. 133 mg, yield 20% (nal product/
quercetin  100%); mp 263 C. ESI-MS: 263.0 [M  H]; ACPI-
MS: 265.0 [M + H]+, 263.0 [M  1]. HRESI-MS found [M + H]+
265.0492; C16H9O4 [M +H]
+ requires 265.0495. Crystal structure,
IR and NMR data were reported in our previous work.17
5: orange powder; 319 mg, yield 48% (nal product/
quercetin  100%); mp 387–388 C. ESI-MS: 457.0 [M + H]+,
455.0 [M  H]; ACPI-MS: 457.0 [M + H]+, 455.0 [M  H].
HRESI-MS found [M + H]+ 457.0554; C25H13O9 [M + H]
+ requires
457.0554. IR (solid, cm1): 3545, 3531, 3288, 3095, 1672, 1646,
1625, 1600, 1577, 1559, 1497, 1438, 1358, 1305, 1278, 1218,


































































































1193, 1166, 1090, 1015, 971, 943, 900, 842, 825, 798, 751, 709,
695. 1H NMR (400 MHz, DMSO-d6) d: 8.12–8.14 (1H, m, H-9),
7.91–7.93 (1H, m, H-6), 7.83–7.87 (1H, m, H-8), 7.76–7.80 (1H,
m, H-7), 7.61–7.63 (1H, d, J¼ 8.3 Hz, H-15), 7.22–7.24 (1H, d, J¼
8.3 Hz, H-14), 6.25 (1H, d, J ¼ 2.0 Hz, H-22), 6.22 (1H, d, J ¼
2.0 Hz, H-24). 13C NMR and DEPT (101 MHz, DMSO-d6) d: 179.9
(C-4), 177.1 (C-19), 175.5 (C-1), 164.3 (C-23), 161.5 (C-21), 157.3
(C-25), 154.7 (C-2), 149.1 (C-17), 145.9 (C-13), 145.4 (C-12), 137.0
(C-18), 135.0 (C-7), 134.4 (C-8), 133.7 (C-10), 132.1 (C-5), 129.8
(C-15), 127.1 (C-6), 126.5 (C-9), 124.5 (C-3), 123.3 (C-11), 116.9
(C-16), 115.0 (C-14), 104.5 (C-20), 98.6 (C-22), 93.9 (C-24). 1H was
assigned to 13C by HSQC correlations. In the 1H–1H COSY
spectrum, the couplings of H-6 with H-7, H-7 with H-8, H-8 with
H-9 were determined. In the HMBC spectrum, the correlations
of H-6 with C-8; H-8 with C-5, 6, 9, 10; H-9 with C-7; H-14 with C-
12, 16; H-15 with C-11, 13, 17; H-22 with C-20, 21, 24; H-24 with
C-20, 22, 25 were observed.
6: brownish red powder; 98 mg, yield 15% (nal product/
quercetin  100%); mp 390–391 C. ESI-MS: 629.0 [M + H]+,
627.0 [MH]; ACPI-MS: 629.0 [M + H]+. HRESI-MS found [M +
H]+ 629.0711; C35H17O12 [M + H]
+ requires 629.0715. IR
(solid, cm1): 3651, 3292, 3125, 2925, 2851, 1654, 1636, 1590,
1560, 1508, 1474, 1368, 1306, 1264, 1215, 1192, 1165, 1090,
1073, 1011, 981, 941, 899, 796, 711, 696. 1H NMR (400 MHz,
DMSO-d6) d: 8.15–8.18 (1H, m, H-9), 8.09–8.11 (1H, m, H-34),
7.99–8.02 (1H, m, H-31), 7.95–7.97 (1H, m, H-6), 7.89–7.91
(1H, m, H-8), 7.88–7.89 (2H, m, H-32, 33), 7.85–7.87 (1H, m, H-
7), 7.62–7.64 (1H, d, J ¼ 8.4 Hz, H-15), 7.48–7.50 (1H, d, J ¼
8.4 Hz, H-14), 6.26–6.27 (1H, d, J ¼ 2.0 Hz, H-22), 6.23–6.24 (1H,
d, J ¼ 2.0 Hz, H-24). 13C NMR and DEPT (101 MHz, DMSO-d6) d:
182.0 (C-29), 181.5 (C-26), 179.8 (C-4), 177.1 (C-19), 175.4 (C-1),
164.4 (C-23), 161.5 (C-21), 157.4 (C-25), 155.2 (C-2), 148.4 (C-
17), 144.8 (C-13), 144.8 (C-12), 137.3 (C-18), 135.8 (C-28), 135.1
(C-7), 135.1 (C-33), 134.7 (C-27), 134.5 (C-8), 134.1 (C-32), 133.7
(C-10), 132.2 (C-5), 131.3 (C-30), 130.9 (C-35), 129.4 (C-15), 127.2
(C-6), 126.6 (C-9), 126.5 (C-34), 126.2 (C-31), 124.2 (C-3), 123.7
(C-11), 120.3 (C-16), 114.3 (C-14), 104.5 (C-20), 98.7(C-22), 94.0
(C-24). 1H was assigned to 13C by HSQC correlations. In the
1H–1H COSY spectrum, the couplings of H-6 with H-7, H-7 with
H-8, H-8 with H-9, H-14 with H-15, H-31 with H-32, H-32 with H-
33, H-33 with H-34 were determined.
7: red needle crystals; 326 mg, yield 66% (nal product/
chalcone  100%); mp 264–265 C. Its crystal structure, MS,
IR and NMR data were reported in our previous work.18
8: red needle crystals; 336 mg, yield 68% (nal product/
chalcone  100%); mp 258–259 C. ESI-MS: 352.2 [M + H]+;
ACPI-MS: 352.2 [M + H]+. HRESI-MS found [M + Na]+ 374.0792,
[2M + Na]+ 725.1689; C23H13NO3Na [M + Na]
+ requires 374.0788,
C46H26N2O6Na [2M + Na]
+ requires 725.1683. IR (solid, cm1):
3690, 3650, 3110, 3098, 3079, 3056, 2956, 2919, 1851, 1667,
1640, 1623, 1588, 1570, 1490, 1466, 1447, 1392, 1365, 1307,
1276, 1227, 1209, 1159, 1134, 1062, 1037, 1018, 998, 905, 877,
834, 808, 758, 748, 706, 693, 662. 1H NMR (500 MHz, CDCl3) d:
9.83–9.85 (1H, d, J ¼ 7.0 Hz, H-11), 8.27–8.29 (1H, d, J ¼ 7.5 Hz,
H-6), 8.03–8.05 (1H, d, J ¼ 7.5 Hz, H-9), 7.97–7.99 (1H, d, J ¼
9.0 Hz, H-14), 7.91–7.93 (2H, d, J ¼ 7.5 Hz, H-19, 23), 7.74–7.77
(1H, td, J¼ 7.5, 1.1 Hz, H-7), 7.65–7.68 (1H, td, J¼ 7.5, 1.1 Hz, H-
8), 7.60–7.63 (1H, t, J ¼ 7.5 Hz, H-21), 7.46–7.49 (2H, t, J ¼
7.5 Hz, H-20, 22), 7.41–7.44 (1H, m, H-13), 7.21–7.24 (1H, t, J ¼
7.3 Hz, H-12). 13C NMR and DEPT (126 MHz, CDCl3) d: 191.9 (C-
17), 180.9 (C-1), 175.0 (C-4), 139.2(C-15), 138.9(C-18), 134.3(C-5),
133.8(C-7), 133.6 (C-10), 133.1 (C-8), 133.1 (C-21), 129.3 (C-19,
23), 128.4 (C-20, 22), 128.4 (C-3), 128.3 (C-13), 127.8 (C-11),
127.2 (C-9), 126.4 (C-6), 121.4 (C-2), 120.4 (C-14), 117.8 (C-12),
113.7 (C-16). 1H was assigned to 13C by HSQC correlations. In
the 1H–1H COSY spectrum, the couplings of H-6 with H-7, H-7
with H-8, H-8 with H-9, H-11 with H-12, H-12 with H-13, H-13
with H-14, H-19 with H-20, H-20 with H-21, H-21 with H-22,
H-22 with H-23 were determined. In the HMBC spectrum, the
correlations of H-6 with C-4, 8, 10; H-7 with C-5, 9; H-8 with C-6,
7, 10; H-9 with C-1, 5, 7; H-11 with C-3, 12, 13, 15; H-12 with C-
13, 14; H-13 with C-11, 12, 15; H-14 with C-12, 15; H-19 with C-
17, 21, 23; H-20 with C-18, 19, 21, 22; H-21 with C-19, 23; H-22
with C-18, 20, 21, 23; H-23 with C-17, 19, 21 were observed.
9: red needle crystals; 389 mg, yield 65% (nal product/
naringenin  100%); mp 318–319 C. ESI-MS: 368.0 [M + H]+,
366.0 [M  H]; ACPI-MS: 368.0 [M + H]+, 366.0 [M  H].
HRESI-MS found [M + H]+ 368.0916; C23H14NO4 [M + H]
+
requires 368.0917. IR (solid, cm1): 3650, 3358, 3071, 1670,
1629, 1614, 1599, 1566, 1560, 1491, 1474, 1436, 1394, 1368,
1306, 1276, 1226, 1211, 1162, 1137, 1063, 1037, 906, 878, 845,
777, 755, 713, 704, 688. 1H NMR (400 MHz, DMSO-d6) d: 10.41
(1H, s, 21-OH), 9.63–9.66 (1H, m, H-11), 8.12–8.15 (1H, m, H-6),
7.91–7.93 (1H, m, H-9), 7.80–7.85 (1H, m, H-7), 7.73–7.77 (4H,
m, H-8,14, 19, 23), 7.47–7.51 (1H, m, H-13), 7.36–7.39 (1H, m, H-
12), 6.80–6.82 (2H, d, J ¼ 8.5 Hz, H-20, 22). 13C NMR and DEPT
(101 MHz, DMSO-d6) d: 189.5 (C-17), 181.1 (C-1), 174.1 (C-4),
162.8 (C-21), 138.1(C-15), 134.6 (C-7), 134.6 (C-5), 133.7 (C-8),
133.5 (C-10), 132.4 (C-19, 23), 130.1 (C-18), 128.3 (C-13), 128.1
(C-11), 127.7 (C-3), 126.9 (C-9), 126.4 (C-6), 120.9 (C-2), 120.1 (C-
14), 118.7 (C-12), 115.7 (C-20, 22), 114.3 (C-16). 1H was assigned
to 13C by HSQC correlations. In the 1H–1H COSY spectrum, the
couplings of H-6 with H-7, H-7 with H-8, H-8 with H-9, H-11 with
H-12, H-12 with H-13, H-13 with H-14, H-19 with H-20, H-22
with H-23 were determined. In the HMBC spectrum, the
correlations of H-6 with C-4, 10; H-7 with C-5, 9; H-8 with C-6,
10; H-9 with C-1, 5, 7; H-11 with C-3, 12, 13, 15; H-12 with C-
11, 13, 14; H-13 with C-11, 15; H-14 with C-12, 15; H-19 with
C-17, 21; H-20 with C-18, 21, 22; H-22 with C-18, 20, 21; H-23
with C-17, 21; 21-OH with 20, 21, 22 were observed.
10: yellow needle crystals; 300–599 mg, yield 20–40% (nal
product/dichlone  100%); mp 296–297 C. ESI-MS: 252.2 [M +
H]+; ACPI-MS: 252.2 [M + H]+. HRESI-MS found [M + H]+
252.0662; C15H10NO3 [M + H]
+ requires 252.0655. 1H NMR (400
MHz, DMSO-d6) d: 8.89–8.91 (2H, d, J ¼ 5.7 Hz, H-11, 15), 8.57–
8.61 (1H, t, J ¼ 7.6 Hz, H-13), 8.15–8.19 (2H, t, J ¼ 6.7 Hz, H-12,
14), 8.05–8.07 (1H, d, J ¼ 7.5 Hz, H-6), 7.96–7.98 (1H, d, J ¼
7.5 Hz, H-9), 7.81–7.85 (1H, t, J¼ 7.4 Hz, H-7), 7.70–7.73 (1H, t, J
¼ 7.3 Hz, H-8). 13C NMR and DEPT (101MHz, DMSO-d6) d: 184.4
(C-1), 172.4 (C-4), 165.4 (C-3), 148.1 (C-11,15), 145.1 (C-13), 134.9
(C-7), 134.1 (C-5), 132.1 (C-8), 131.6 (C-10), 127.4 (C-12, 14),
126.5 (C-9), 126.3 (C-6), 125.4 (C-2). 1H was assigned to 13C by
HSQC correlations. In the 1H–1H COSY spectrum, the couplings
of H-6 with H-7; H-7 with H-8; H-8 with H-9; H-13 with H-12, 14;


































































































H-11 with H-12; H-14 with H-15 were determined. In the HMBC
spectrum, the correlations of H-6 with C-4, 10; H-7 with C-5, 9;
H-8 with C-6, 10; H-9 with C-1, 5; H-11, 15 with C-13; H-13 with
C-11, 15; H-12 with C-11; H-14 with C-15; H-12 with C-14; H-14
with C-12 were observed.
3.2 Synthesis and isolation
One of the selected avonoids (0.002 mol) was mixed with
dichlone (0.006 mol) uniformly, and then 50 mL of pyridine was
added to dissolve the mixed solid in a 100-mL double mouth
round bottom ask. The reacting system was stirred at 85 C for
24 h (in order to synthesize 4, 7, 8, 9, additional conditions, air
being pumped through a water-lled absorption bottle and then
injected into this mixture solution with ow velocity of 1
bubble/2 s, must be provided), and was nally concentrated to
give a semi-solid mass. The mass was chromatographed on
Biotage Isolera Four ash column chromatography system with
a SNAP Cartridge KP-Sil 10 g column eluted by hexane/ethyl
acetate (100 : 0 to 90 : 10, v/v), and then by chloroform/
methanol (100 : 0 to 90 : 10, v/v) to give fractions. TLC was
used to distinguish the eluted fractions. The fractions were
further isolated by preparative TLC (1000 microns; 20 cm  20
cm) using chloroform/methanol or hexane/ethyl acetate as
developing agent to yield derivatives.
3.3 Assay for anticancer activity
Cytotoxicity against non-solid tumor and solid tumor were
tested by Trypan blue dye exclusion method and Neutral red
uptake method, respectively.21 IC50 was calculated from the
dose curves generated by plotting percent growth vs. the test
concentration on a logarithmic scale using Microso Excel. All
assays were performed in triplicate and the mean values are
given in Table 1.
3.4 Apoptosis analysis
The sensitive cancer cell lines were separately incubated with
derivatives, DMSO and doxorubicin (positive control) at
different concentrations for 24 h, harvested by centrifugation at
300g, washed twice with cold 1 PBS and resuspended in 100 mL
of binding buffer at a density of 2  106 cells per mL, stained
with 5 mL of PE Annexin-V and 5 mL of 7-AAD for 15 min in the
dark at room temperature and nally subjected to analysis via
Accuri™ C6 ow cytometry.22,23
3.5 Western blotting analysis
The sensitive cancer cell lines were separately treated with
derivatives, doxorubicin (positive control) and DMSO at
different concentrations for 24 h, washed with cold 1 PBS,
harvested in RIPA lysis solution for 60 min on ice, and then
heated to boiling point for 10 min aer adding loading buffer.
The cell lysate were centrifuged at 13 000 g for 10 min at 4 C.
Equal amounts of the protein samples were subjected to SDS-
PAGE electrophoresis and transferred to PVDF membranes.
The membranes were blocked in 5% nonfat milk, incubated
with diluted primary antibodies and secondary antibodies
conjugated with HRP, treated with Western Lighting Chem-
iluminescence Reagent and nally visualized on biomolecular
imager to determine the expression levels of apoptosis marker
proteins including caspase-3 and PARP cleavage (using b-actin
as internal reference).23,24
4. Conclusion
By the common base-catalyzed method, not only mono
condensation products (1, 5) but also bis-naphthoquinones
compounds (2, 3, 6) were obtained.
Through a newmethod of combining base-catalyzed with O2/
H2O exposing, benzonaphthofuroquinone (4) and benzoyl-
naphthindolizinediones (7, 8, 9) were synthesized. To our
knowledge this is the rst report about the reaction of chalcone/
dihydroavone with dichlone under given conditions to
produce benzoylnaphthindolizinediones, as well as the reaction
of avonols with dichlone to achieve benzonaphthofur-
oquinones. Benzoylnaphthindolizinediones were previously
synthesized by methods of potassium carbonate-catalyzing,11 or
copper(II)-catalyzing,12 or iodine oxidation.13
Some of the derivatives (2, 3, 4, 5) showed good anticancer
activities and low toxicity to normal cells, which indicated that
they possess some cytotoxic selectivity. The formed furan-ring
in benzonaphthofuroquinones being replaced by pyrrol-ring
in benzoylnaphthindolizinediones resulted in the loss of anti-
cancer activity. Late-stage-apoptosis and caspase-3 pathway may
contribute to the cytotoxicities of the synthesized
benzonaphthofuroquinones.
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